Royalty Pharma plc - Ordinary Shares - Class A

NASDAQ:RPRX   4:00:00 PM EDT
28.41
-0.35 (-1.22%)
: $28.50 +0.09 (+0.32%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)12.66B
Current PE7.44
Forward PE 7.21
2yr Forward PE 6.52
See more stats
Estimates Current Quarter
Revenue$671.45 Million
Adjusted EPS$0.95
See more estimates
10-Day MA$28.25
50-Day MA$29.32
200-Day MA$28.46
See more pivots

Royalty Pharma plc - Ordinary Shares - Class A Stock, NASDAQ:RPRX

110 East 59th Street, 33rd floor, New York, New York 10022
United States of America
Phone: +1.212.883.0200
Number of Employees: 89

Description

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J�s Imbruvica, Astellas and Pfizer�s Xtandi, Biogen�s Tysabri, Gilead�s HIV franchise, Merck�s Januvia, Novartis� Promacta, Vertex�s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.